<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24278177</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>11</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers.</ArticleTitle><Pagination><StartPage>e79783</StartPage><MedlinePgn>e79783</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e79783</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0079783</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Enterovirus 71 (EV71) has caused several epidemics of hand, foot and mouth diseases (HFMD) in Asia. No effective EV71 vaccine is available. A randomized and open-label phase I clinical study registered with ClinicalTrials.gov #NCT01268787, aims to evaluate the safety, reactogenicity and immunogenicity of a formalin-inactivated EV71 vaccine candidate (EV71vac) at 5- and 10-&#xb5;g doses. In this study we report the cross-neutralizing antibody responses from each volunteer against different subgenotypes of EV71 and CVA16.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Sixty eligible healthy adults were recruited and vaccinated. Blood samples were obtained on day 0, 21 and 42 and tested against B1, B4, B5, C2, C4A, C4B and CVA16 for cross-neutralizing antibody responses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The immunogenicity of both 5- and 10- &#xb5;g doses were found to be very similar. Approximately 45% of the participants had &lt;8 pre-vaccination neutralization titers (Nt) against the B4 vaccine strain. After the first EV71vac immunization, 95% of vaccinees have &gt;4-fold increase in Nt, but there was no further increase in Nt after the second dose. EV71vac induced very strong cross-neutralizing antibody responses in &gt;85% of volunteers without pre-existing Nt against subgenotype B1, B5 and C4A. EV71vac elicited weak cross-neutralizing antibody responses (&#x223c;20% of participants) against a C4B and Coxsackie virus A16. Over 90% of vaccinated volunteers did not develop cross-neutralizing antibody responses (Nt&lt;8) against a C2 strain. EV71vac can boost and significantly enhance the neutralizing antibody responses in volunteers who already had pre-vaccination antibodies against EV71 and/or CVA16.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">EV71vac is efficient in eliciting cross-neutralizing antibody responses against EV71 subgenotypes B1, B4, B5, and C4A, and provides the rationale for its evaluation in phase II clinical trials.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT01268787.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Ai-Hsiang</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Vaccine Research &amp; Development Center, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chyi</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Jui-Yuan</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Renee</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Yi-Chin</ForeName><Initials>YC</Initials></Author><Author ValidYN="Y"><LastName>Tsao</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chien-Long</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ju-Lan</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Fung</LastName><ForeName>Chang-Phone</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Szu-Min</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ya-Fang</ForeName><Initials>YF</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jen-Ren</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Mei-Hua</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Jen-Ron</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Ih-Jen</ForeName><Initials>IJ</Initials></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Pele Choi-Sing</ForeName><Initials>PC</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01268787</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>1HG84L3525</RegistryNumber><NameOfSubstance UI="D005557">Formaldehyde</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005557" MajorTopicYN="N">Formaldehyde</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>11</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24278177</ArticleId><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0079783</ArticleId><ArticleId IdType="pii">PONE-D-13-09324</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McMinn PC (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26: 91&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Qian Y, Wang S, Serrano JMG, LI W, et al. (2010) EV71: An emerging infectious disease vaccine target in the Far East? Vaccine 10.1016/j.vaccine.2010.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.03.003</ArticleId><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Chang LY (2010) Development of enterovirus 71 vaccines. Expert Rev Vaccines 9: 149&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">20109026</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cordosa MJ, McMinn P, et al. (2010) Virology, epidemiology, pathogenesis and control of enterovirus 71. Lancet Infect Dis 10: 778&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang CP, Guo MH, Hsieh SY, et al. (2012) Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS One 7 (4) e34834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3328501</ArticleId><ArticleId IdType="pubmed">22529942</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, et al. (2012) Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: A randomized, placebo-controlled, doble-blind, phase 1 clinical trial. Vaccine 10.1016/j.vaccine.2012.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.03.010</ArticleId><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH (1974) An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129: 304&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Pallansch MA (1995) Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res 39: 195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Lin FHY, Hsiao KN, Chang KHW, et al. (2011) Purification and characterization of EV71 viral particles produced from Vero cell grown in a serum-free microcarrier bioreactor system. PLoSONE 10.1371/journal.pone.0020005</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020005</ArticleId><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Bible JM, Iturriza-Gomara M, Megson B, Brown D, Pantelidis P, et al. (2008) Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J. Clin. Microbiol 46: 3192&#x2013;3200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566106</ArticleId><ArticleId IdType="pubmed">18650362</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan YF, Sam JC, Abubakar SC (2010) Phylogenetic designation of EV71 genotypes and subgenotypes using complete genome sequences. Infection, Genetics and Evolution 10: 404&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19465162</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Hsu YW, Smith DJ, Kiang D, Tsai HP, et al. (2009) Reemergence of enterovirus 71 in 2008 in Taiwan: Dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Mincrobiol 47: 3653&#x2013;3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772620</ArticleId><ArticleId IdType="pubmed">19776232</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, et al. (2002) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Lian WC, Butler M, Wu SC (2007) High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine 25: 19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16919374</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, Rosli R (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5: 6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, et al. (2011) Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 29: 4829&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">21550375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Liu L, Zhao H, Wang J, Liao Y, et al. (2011) Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 29: 6269&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chang HW, Yang G, Chiang JR, Chow YH, et al. (2011) Development of a quantitative enzyme linked immunosorbent assay for monitoring the EV71 vaccine manufacturing process. J Virol Methods 10.1016/j.jviromet.2011.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2011.06.001</ArticleId><ArticleId IdType="pubmed">21704080</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, et al. (2011) Identification and characterization of a cross-neutralization epitope of EV71. Vaccine 29: 4362&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang HW, Liu CC, Lin MH, Ho HM, Yang YT, et al. (2011) Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genotype B isolates. J Virol Methods 173: 189&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">21315763</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JY, Chang CP, Tsai HHP, Lee CD, Lian WC, et al. (2012) Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine 30: 703&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">22142585</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang JY, Lien SP, Guo MH, et al. (2012) Immunological evaluation and comparison of different EV71 vaccine candidates. Clinical and Developmental Immunology 10.1155/2012/831282</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/831282</ArticleId><ArticleId IdType="pmc">PMC3447357</ArticleId><ArticleId IdType="pubmed">23008736</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, et al. (2012) Production of EV71 vaccine candidates. Human Vaccines &amp; Immunotherapeutics 8 (12) 1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3656065</ArticleId><ArticleId IdType="pubmed">22992566</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng A, Fung CF, Liu CC, Lin YT, Tsai HY, et al. (2013) A phase 1, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 31: 2471&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">23541623</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H (1938) A simple method of estimating 50 percent end-points. Am J Hyg 27: 493&#x2013;497.</Citation></Reference><Reference><Citation>Meng FY, Li JX, Li XL, Chu K, Zhang YT, et al. (2012) Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: An open label, phase 1 clinical trial. Hum Vaccin Immunother 8 (5) 668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">22634437</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>